Scores for the VSS and CSS were calculated by applying a uniform computer program code across all episodes in the dataset.

Because the trials were this website originally planned and conducted as two regional trials in Africa and Asia, this analysis focused on each region separately, with sub-analyses conducted by site. Within each region the two clinical scoring systems were compared similar to what was done by Givon-Lavi et al. [23] and Ruuska and Vesikari [20]. Demographic and clinical information such as site (i.e. country), gender, hospitalization status (i.e. hospitalization or receipt of IV therapy), and age was compared between each scoring system for rotavirus and non-rotavirus

gastroenteritis cases. Mean scores and proportions of participants meeting severe criteria according to each scoring system were calculated. To demonstrate the differences between each item score for the two scoring systems, the item scoring distributions for each sign/symptom commonly included in the clinical scoring systems GDC-0199 in vitro were compared and the VSS to CSS ratio of the numbers of participant episodes with each item point score calculated. Chi-Square or, when appropriate, Fisher’s Exact tests, Student’s t-tests, or ANOVAs were used to test for statistical GPX6 significance of contingency tables and continuous variables, respectively. The scoring system severity classifications were compared between the VSS and the CSS based on the “original” and two “modified” severity classifications. The original inhibitors classification is based on the mild, moderate, and

severe cut points historically used for defining severity; VSS: <7 mild, 7–10 moderate, and ≥11 severe, CSS: <9 mild, 9–16 moderate, and ≥17 severe. The original classification is based on consistency with the original severity classification method used by Ruuska and Vesikari [20], where the threshold was selected as the mean score (i.e. severe ≥11), also corresponding to the median score in the scoring distribution for this study. Modified classifications were also used in this study. One modified classification used the mean VSS severity score observed among rotavirus-positive participants in these trials in Africa (≥10) and Asia (≥11) as the severity threshold and compared these to a CSS severity threshold based on the mean in each region (Africa and Asia: ≥10). A second modified classification comparison set the severity threshold at the median of the scoring distribution (VSS: ≥11/20 points; CSS ≥13/24 points).